BIOCON - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 2.7
| Stock Code | BIOCON | Market Cap | 59,785 Cr. | Current Price | 369 ₹ | High / Low | 425 ₹ |
| Stock P/E | 307 | Book Value | 120 ₹ | Dividend Yield | 0.14 % | ROCE | 2.09 % |
| ROE | 0.40 % | Face Value | 5.00 ₹ | DMA 50 | 382 ₹ | DMA 200 | 372 ₹ |
| Chg in FII Hold | 0.53 % | Chg in DII Hold | 2.07 % | PAT Qtr | 111 Cr. | PAT Prev Qtr | 70.9 Cr. |
| RSI | 38.2 | MACD | -0.43 | Volume | 20,42,265 | Avg Vol 1Wk | 30,48,094 |
| Low price | 295 ₹ | High price | 425 ₹ | PEG Ratio | -16.5 | Debt to equity | 0.16 |
| 52w Index | 56.5 % | Qtr Profit Var | 3,183 % | EPS | 0.07 ₹ | Industry PE | 27.2 |
📊 Analysis: BIOCON is trading at ₹369, slightly below its 50 DMA (₹382) and near its 200 DMA (₹372), reflecting weak technical strength. RSI at 38.2 indicates low momentum, while MACD at -0.43 suggests mild bearish bias. Current volume (20,42,265) is lower than the 1-week average (30,48,094), showing reduced intraday participation. Despite strong quarterly profit growth, extremely high P/E and weak efficiency ratios make intraday trading risky.
💰 Optimal Buy Price: ₹360–365 (near support zone)
📈 Profit-Taking Levels: ₹375–385 (short-term resistance)
📉 Stop-Loss: ₹355 (below support)
⏳ If Already Holding: Exit intraday if price fails to sustain above ₹372 or if momentum indicators remain weak. A bounce toward ₹375–385 can be used for profit booking, while a breakdown below ₹360 should trigger exit to protect capital.
✅ Positive
- Quarterly PAT growth from ₹70.9 Cr. to ₹111 Cr. (+3,183% YoY variation).
- DII holding increased (+2.07%), showing strong domestic institutional support.
- FII holding also increased (+0.53%), reflecting foreign investor confidence.
- Debt-to-equity ratio at 0.16 is manageable.
⚠️ Limitation
- Extremely high P/E ratio (307) compared to industry average (27.2).
- Weak ROCE (2.09%) and ROE (0.40%) highlight poor efficiency.
- Volume significantly below average, limiting intraday momentum.
📉 Company Negative News
- EPS at ₹0.07 remains very low despite profit growth.
- Stock trading below both 50 DMA and 200 DMA, confirming weak sentiment.
📈 Company Positive News
- Strong quarterly profit growth supports earnings momentum.
- Institutional support from both FII and DII holdings.
🏭 Industry
- Biopharma sector remains promising with long-term demand visibility.
- Industry P/E at 27.2 shows sector is moderately valued compared to BIOCON’s extreme valuation.
🔎 Conclusion
BIOCON shows strong profit growth and institutional support, but extremely high valuation and weak efficiency ratios make intraday trading risky. Suitable only for cautious trades near support zones with strict stop-loss discipline. Momentum indicators suggest limited upside unless volume improves significantly.